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Transcatheter Aortic Valve Implantation
Assessing the Learning Curve
Oluseun O. Alli, MD,* Jeffrey D. Booker, MD,* Ryan J. Lennon, MS,‡
Kevin L. Greason, MD,† Charanjit S. Rihal, MD,* David R. Holmes, JR, MD*
Rochester, Minnesota
Objectives The aim of this study was to assess the learning curve for the implantation of the per-
cutaneous aortic valve via the transfemoral route.
Background Transcutaneous aortic valve insertion is a fundamentally new procedure for the treat-
ment of aortic valve stenosis. The number of cases needed to gain proﬁciency with concomitant
ease and familiarity (i.e., the “learning curve”) with the procedure is unknown.
Methods We performed a retrospective analysis of the ﬁrst 44 consecutive patients who underwent
transcatheter aortic valve implantation as part of the PARTNER (Placement of Aortic Transcatheter
Valves) trial at our institution between November 2008 and May 2011.
Results The median age of the patients was 83 years (interquartile range: 77 to 87 years) and a
median Society of Thoracic Surgery risk score of 9.6. Pre-procedural assessment of the aortic valve
revealed a mean gradient of 53.5 mm Hg, mean aortic valve area of 0.7 mm2, and a median ejection
raction of 59.5%. Patients were divided into tertiles based on sequence. Signiﬁcant decreases in
edian contrast volume (180 to 160 to 130 ml, p  0.003), valvuloplasty to valve deployment time
12.0 to 11.6 to 7.0 min, p  0.001) and ﬂuoroscopy times, from 26.1 to 17.2 and 14.3 min occurred
rom tertiles 1 to 3, p  0.001. Signiﬁcant decreases in radiation doses were also seen across the
tertiles, p  0.001. The 30-day mortality for the entire cohort was 11%.
onclusions Experience accumulated over 44 transfemoral aortic valve implantations led to signiﬁ-
ant decreases in procedural times, radiation, and contrast volumes. Our data show increasing proﬁ-
iency with evidence of plateau after the ﬁrst 30 cases. More studies are needed to conﬁrm these
ndings. (J Am Coll Cardiol Intv 2012;5:72–9) © 2012 by the American College of Cardiology
oundation
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73Severe symptomatic aortic stenosis is a lethal condition if
left untreated (1–5). Definitive treatment for this condition
has been surgical aortic valve replacement (AVR) as medical
therapy is palliative in nature (6,7). Unfortunately, there are
an increasing number of patients with significant comor-
bidities that preclude them from undergoing surgical AVR
or that confer a marked increase in surgical risk. Therefore,
many of these patients are either not referred to a surgeon or
are turned down for surgery because of the prohibitively
high surgical risk (7–10).
See page 80
Transcatheter aortic valve implantation (TAVI) has
emerged as an alternative for these high risk or inoperable
patients (11–14). The first TAVI with a balloon expandable
valve was performed in 2002 (15) and over 10,000 valves
have been implanted percutaneously in Europe. In the
United States, the results of the recently concluded PARTNER
(Placement of Aortic Transcatheter Valves) study have been
presented and published (16). Among inoperable patients
with severe aortic stenosis treated with TAVI, there was a
20% absolute risk reduction in mortality with a concom-
itant reduction in the composite endpoints of cardiac
mortality, repeat hospitalization, or cardiac symptoms
compared with standard medical therapy (16). The re-
cently released PARTNER Cohort A results demon-
strated noninferiority of TAVI compared with surgical
AVR in high-risk patients (17).
Because percutaneous valve therapies are a new field,
physicians and surgeons involved in the implantation of
these valves need to undergo training and accumulate
experience and knowledge to achieve optimal procedural
performance. There have been several studies detailing
the implantation, performance, and outcomes of these
valves (16,18 –28); however, there is paucity of data
regarding the actual learning experience associated with
the technique.
The aim of this study was to assess the learning curve
of the physicians and team involved in the implantation
of the transcutaneous aortic valve via the transfemoral
route at a single institution involved in the PARTNER
trial. We hypothesized that a quantifiable learning curve
exists for TAVI and that process measures of procedural
proficiency would improve with case numbers. We de-
fined proficiency as a significant (p  0.05) reduction in
the process measures of procedure time, radiation dose,
and contrast volume.
Methods
The study was approved by the Mayo Clinic Institutional
Review Board and was a retrospective review of 44 consec-
utive patients (n  22 in Cohort A, n  22 in Cohort B)undergoing transfemoral aortic valve implantation as part of
the PARTNER trial at our institution between November
2008 and May 2011. During this period, approximately 670
patients with severe aortic stenosis were seen and evaluated:
565 patients did not meet study criteria, whereas 98 patients
received the Edwards Sapien valve (Edwards Lifesciences,
Irvine, California) via either the transfemoral or the
transapical approach. All adverse events are confirmed by
reviewing the medical records of the patients followed at
Mayo Clinic and by contacting the patients’ physicians and
reviewing the hospital records of patients treated elsewhere.
All patients were seen and managed by a heart team,
including general cardiologists, interventional cardiologists,
nurses, cardiac anesthesiologists, and cardiac surgeons. Pre-
operative echocardiography was obtained to determine the
severity of aortic stenosis and patients were offered TAVI
based on the protocol of the PARTNER trial (29).
After enrollment, all patients underwent a systematic
evaluation, including coronary angiography with revascular-
ization as indicated and Doppler echocardiography. Com-
puted tomography (CT) was performed to determine the
size and the anatomy of the il-
iofemoral and aortic vasculature.
Other tests included pulmonary
function testing, complete blood
counts, serum electrolytes, liver
function tests, and coagulation
studies. Medications were mod-
ified and adjusted as necessary,
and baseline comorbidities were
appropriately managed to ensure
the optimization of their medi-
cal status before the procedure.
Assessment of the learning curve. This study was not pow-
red to examine outcome variables as a reflection of proce-
ural proficiency and learning. Process measures, such as
rocedure times, radiation exposure, and contrast adminis-
ration were chosen as markers for increased procedural
roficiency.
Study device and procedure. The aortic valve implantation
s performed in the cardiac catheterization laboratory by 1 to
interventionalists and a cardiac surgeon. The technical
etails of the transfemoral procedure have been previously
escribed (30). This current analysis details patients treated
ith either the 23-mm or 26-mm Edwards Sapien XT valve
ith the retroflex 3 delivery system using the 22- or 24-F
heaths.
Statistical analysis. Procedure order was assessed as a con-
tinuous variable, and patients were further divided into
tertiles according to procedure order for ease of presentation
of summary statistics. However, to increase statistical
power, hypothesis tests involving procedure order were
conducted on the absolute order value, rather than on the
Abbreviations
and Acronyms
AVR  aortic valve
replacement
CT  computed tomography
IQR  interquartile range
TAVI  transcatheter aortic
valve implantation
TEE  transesophageal
echocardiographytertiles. Continuous variables were summarized as median
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74(25th, 75th percentiles). Discrete variables were presented
as frequency (percentage). Temporal trends were tested in
continuous variables using Spearman correlation coefficient.
For binary variables, temporal trends were tested using a
Wilcoxon 2-sample test to test the distribution of patient
order between the 2 groups (e.g., with vs. without coronary
artery disease). A locally weighted scatterplot smoother was
used to demonstrate temporal trends on scatterplots with
patient order as the variable on the horizontal axis.
Results
Table 1 shows the baseline characteristics of the cohort.
imilar to the overall PARTNER trial, the median age was
3 years (interquartile range [IQR]: 77 to 87 years) with a
edian Society of Thoracic Surgeons risk score of 9.6;
2 (50%) were men, 30 (68%) had coronary artery disease,
nd 24 (55%) had hypertension. Pre-procedural assessment
f the aortic valve revealed a mean gradient of 53.5 mm Hg
IQR: 50 to 61 mm Hg), with an aortic valve area of 0.7
m2 (IQR: 0.6 to 0.8 mm2) and ejection fraction of 59.5%
IQR: 43% to 67.5%) (Table 2).
Table 3 details the procedural characteristics for the
ntire cohort.
Patients were divided into tertiles, with approximately 15
atients in each group, based on sequence number (Table 4).
atients in tertiles 2 and 3 compared with patients in tertile
were significantly older (p  0.016) but were less likely to
e obese (p 0.019) or suffer from sleep apnea (p 0.023).
here were no significant differences in pre-procedural valve
haracteristics between the 3 groups (Table 5). Technical
uccess, defined as successful valve implantation was
chieved in all but 1 patient, who had small iliac arteries that
recluded placement of the large bore sheath. One patient
ad a repeat valve-in-valve procedure for severe prosthetic
ortic regurgitation with congestive heart failure. Five pa-
Table 1. Baseline Characteristics for the Entire Cohort
Age, yrs 83 (77, 87)
Male 22 (50%)
Coronary artery disease 30 (68%)
Hypertension 24 (55%)
Cerebrovascular disease 7 (16%)
Pulmonary hypertension 9 (20%)
Dyslipidemia 22 (50%)
Diabetes mellitus 10 (23%)
Obstructive sleep apnea 9 (20%)
Obesity 6 (14%)
Atrial ﬁbrillation/ﬂutter 14 (32%)
Anemia 9 (20%)
Chronic kidney disease 12 (27%)
Aortic calciﬁcation 6 (14%)
Chronic obstructive pulmonary disease 13 (30%)Values are median (Q1, Q3) or n (%).ients died by 30 days (11%). The causes of death included
cute aortic valve thrombosis, large ischemic/embolic cere-
rovascular accident, sudden cardiac death, severe retroper-
toneal bleed, and acute hypoxic respiratory failure.
The learning curve was assessed by measurement of
ntraprocedural process parameters. As shown in Table 6,
here was a nonsignificant decrease in pacing runs and the
umber of aortograms across the 3 tertiles. Significant
ifferences were seen in cutdown-to-sheath and cutdown-
o-valvuloplasty times, from medians of 42.5 to 43.1 to 19.0
in and 61.5 to 51.7 to 42.5 min, p 0.002 and p 0.001,
espectively. The continued trend toward decreases in in-
raprocedural times is shown in Figure 1. A significant
ecrease in contrast volume was seen across the 3 tertiles
median: 180 to 160 to 130 ml, p  0.003). Similarly
ignificant decreases were also seen in valvuloplasty-to–valve
eployment time decreasing from 12.0 to 11.6 and 7.0 min
rom tertiles 1 to 3, respectively, p 0.001, and fluoroscopy
imes, from 26.1 to 17.2 and 14.3 min, respectively, from
ertiles 1 to 3, p  0.001. Concomitant, significant de-
reases in radiation doses were also seen across the 3 tertiles,
Table 2. Pre- and Post-Echocardiographic Parameters (n  44)
Mean gradient before 53.5 (50.0, 61.0)
Aortic valve area before 0.7 (0.6, 0.8)
Ejection fraction before 59.5 (43.0, 67.5)
RVSP before 44.0 (32.0, 53.0)
Valve size, mm 23.0 (23.0, 26.0)
Mean gradient after 6.0 (4.0, 8.0)
Aortic insufﬁciency after 1.0 (1.0, 2.0)
Mean gradient at follow-up 13.0 (10.0, 16.0)
Aortic valve area at follow-up 2.0 (1.7, 2.3)
Ejection fraction at follow-up 64.0 (56.0, 69.0)
RVSP at follow-up 40.5 (32.0, 56.5)
Aortic insufﬁciency at follow-up 2.0 (1.0, 2.0)
Values are median (Q1, Q3). Aortic insufficiency: trivial AI1, mild AI 2, mild to moderate AI 3,
moderate AI 4.
Q quartile; RVSP right ventricular systolic pressure.
Table 3. Procedural Characteristics (n  30)
Contrast volume 150.0 (120.0, 180.0)
Inﬂation count 1.0 (1.0, 1.0)
Aortogram count 6.0 (5.0, 8.0)
Pacing count 3.0 (2.0, 4.0)
Cutdown to sheath, min 39.2 (28.0, 46.4)
Cutdown to valvuloplasty, min 51.0 (43.0, 64.0)
Valvuloplasty to deployment, min 10.5 (7.0, 12.3)
Fluoroscopy time 17.9 (14.7, 25.7)
Total dose 849.0 (585.0, 1822.0)
Vascular complication 7.0 (16%)
30-day survival 39.0 (89%)
Length of stay 6.0 (4.0, 8.0)Values are median (Q1, Q3) or n (%).
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75p  0.001. This is also shown in Figure 2, where the
scatterplot shows a clear downward trend. The scatterplots
demonstrate less variation with more of a plateau at approx-
imately 30 cases with maintenance of this consistency going
forward. There was a nonsignificant decrease in the rates of
vascular complication from tertiles 1 to 3.
Discussion
The main findings of the current study are: 1) physicians
and teams performing TAVI procedures became more
proficient and measures of the learning curve effect im-
proved with an increasing number of procedures performed,
including, specifically; 2) a clear decrease in intraprocedural
times; and 3) significant decreases in contrast and radiation
dose with increasing case volumes.
Table 4. Baseline Characteristics by Tertile
Patients #1–#15 (n  15)
Age, yrs 79 (73, 83)
Male 8 (53%)
Coronary artery disease 12 (80%)
Hypertension 7 (47%)
Cerebrovascular disease 3 (20%)
Pulmonary hypertension 3 (20%)
Dyslipidemia 9 (60%)
Diabetes mellitus 4 (27%)
Obstructive sleep apnea 5 (33%)
Obesity 5 (33%)
Atrial ﬁbrillation/ﬂutter 5 (33%)
Anemia 3 (20%)
Chronic kidney disease 4 (27%)
Aortic calciﬁcation 2 (13%)
Chronic obstructive pulmonary disease 4 (27%)
Values are median (Q1, Q3) or n (%).
Table 5. Pre- and Post-Echocardiographic Parameters by Tertile
Patients #1–#15 (n  15) Patient
MG before 57.0 (50.0, 60.0) 5
AVA before 0.8 (0.6, 0.8)
EF before 58.0 (50.0, 67.0) 5
RVSP before 41.0 (32.0, 60.0) 4
Valve size 23.0 (23.0, 26.0) 2
MG after 5.0 (4.0, 8.0)
AI after 1.0 (1.0, 2.0)
MG at follow-up 14.0 (11.0, 17.0) 1
AVA at follow-up 2.0 (1.7, 2.2)
EF at follow-up 61.0 (56.0, 68.0) 6
RVSP at follow-up 35.0 (29.0, 41.0) 4
AI at follow-up 1.0 (1.0, 2.0)
Values are median (Q1, Q3). Aortic Insufficiency: trivial AI 1, mild AI 2, mild to moderate AI 3AI aortic insufficiency; AVA aortic valve area; EF ejection fraction; MGmean gradient; RVSP rTAVI should have a significant impact on the care and
management of patients with aortic stenosis who are either
inoperable or at high risk for conventional aortic valve surgery.
These procedures, however, are technically complex and re-
quire a skill set markedly different from coronary interventions.
The safe introduction of TAVI into the clinical environment
will require careful training and case number guidelines. This
percutaneous procedure requires close collaboration between
cardiac surgeons and the interventional cardiologists, with both
specialties bringing to bear their expertise with cutdown and
exposure of the femoral artery, insertion of large bore arterial
sheaths, balloon aortic valvuloplasty, and careful placement of
the aortic valve prosthesis during rapid ventricular pacing.
Numerous interventional procedures, such as percutaneous
coronary interventions, carotid artery stenting, endovascular
aortic aneurysm repair, pulmonary valve implantation, and
ients #16–#29 (n  15) Patients #30–#44 (n  14) p Value
85 (77, 90) 85.5 (78.0, 87.0) 0.016
8 (53%) 6 (43%) 0.99
10 (67%) 8 (57%) 0.16
7 (47%) 10 (71%) 0.36
1 (7%) 3 (21%) 0.95
4 (27%) 2 (14%) 0.73
6 (40%) 7 (50%) 0.23
1 (7%) 5 (36%) 0.73
3 (20%) 1 (7%) 0.023
1 (7%) 0 (0%) 0.019
5 (33%) 4 (29%) 0.93
2 (13%) 4 (29%) 0.58
2 (13%) 6 (43%) 0.28
3 (20%) 1 (7%) 0.69
5 (33%) 4 (29%) 0.55
–#29 (n  15) Patients #30–#44 (n  14) p Value
.0, 65.0) 55.5 (50.0, 62.0) 0.70
6, 0.9) 0.7 (0.7, 0.8) 0.76
.0, 69.0) 64.0 (56.0, 68.0) 0.52
.0, 49.0) 42.0 (30.0, 53.0) 0.73
.0, 26.0) 23.0 (23.0, 23.0) 0.40
0, 10.0) 6.0 (4.0, 7.0) 0.39
0, 2.0) 1.0 (1.0, 2.0) 0.25
0, 18.0) 11.0 (10.0, 13.0) 0.074
6, 2.3) 2.2 (2.0, 2.5) 0.064
.0, 69.0) 64.0 (48.0, 69.0) 0.82
.0, 57.0) 44.0 (32.0, 58.0) 0.064
0, 4.0) 2.0 (1.0, 2.0) 0.33
ate AI 4.Pats #16
2.0 (47
0.7 (0.
7.0 (42
4.0 (37
6.0 (23
6.0 (4.
1.0 (1.
3.0 (9.
1.8 (1.
5.0 (56
1.0 (34
2.0 (1.
, moderight ventricular systolic pressure.
w
c
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 5 , N O . 1 , 2 0 1 2
J A N U A R Y 2 0 1 2 : 7 2 – 9
Alli et al.
TAVI and Learning Curve
76percutaneous balloon mitral valvuloplasty have evidence of a
clear learning curve (31–35). The present study also shows that
this is true for TAVI; a definite procedure-related learning curve
as seen as evidenced by our decreased procedural and fluoros-
opy times with reduced contrast volume and complications. The
Table 6. Procedural Characteristics by Tertile
Patients #1–#15 (n  15)
Contrast volume 180.0 (130.0, 250.0)
Inﬂation count 2.0 (1.0, 2.0)
Aortogram count 8.0 (4.0, 9.0)
Pacing count 4.0 (3.0, 7.0)
Cutdown to sheath, min 42.5 (33.4, 46.4)
Cutdown to valvuloplasty, min 61.5 (51.0, 68.0)
Valvuloplasty to deployment, min 12.0 (11.0, 19.4)
Fluoroscopy time 26.1 (19.6, 30.5)
Total dose 1822.0 (1,109.0, 3,803.0)
Vascular complication 3.0 (20%)
30-day survival 11.0 (73%)
Length of stay 5.0 (4.0, 9.0)
Values are median (Q1, Q3) or n (%).
Figure 1. Scatterplot Showing the Trend Toward a Decrease in
Intraprocedural Parameters MeasuredLoess  locally weighted scatterplot smoothing; V-plasty  valvuloplasty.observed 30-day mortality rate in the current study is comparable
to those of other trials of TAVI (20,23–25).
We believe the reasons for improvement are multifacto-
rial, including refinement of procedural techniques, patient
selection, and coordination of patient care among all the
tients #16–#29 (n  15) Patients #30–#44 (n  14) p Value
160.0 (140.0, 200.0) 130.0 (105.0, 150.0) 0.003
1.0 (1.0, 1.0) 1.0 (1.0, 1.0) 0.020
6.0 (4.0, 8.0) 6.0 (5.0, 6.0) 0.52
3.0 (2.0, 4.0) 3.0 (2.0, 3.0) 0.057
43.1 (37.5, 52.8) 19.0 (18.0, 35.9) 0.002
51.7 (45.7, 65.7) 42.5 (38.0, 46.4) 0.001
11.6 (7.1, 12.3) 7.0 (5.0, 8.0) 0.001
17.2 (14.7, 21.3) 14.3 (12.1, 16.3) 0.001
849.0 (610.0, 1245.0) 585.0 (506.0, 728.0) 0.001
3.0 (21%) 1.0 (7%) 0.13
15.0 (100%) 13.0 (93%) 0.22
6.0 (4.0, 9.0) 5.0 (5.0, 8.0) 0.96
Figure 2. Scatterplot Showing the Trend Toward a Decrease in
Contrast Volume and Radiation ExposurePaLoess  locally weighted scatterplot smoothing.
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77caregivers. Numerous aspects to a learning curve exist. We
took a holistic approach to the learning curve and incorpo-
rated case selection, cognitive learning, and technical profi-
ciency. We are not able to parse out which aspect of learning
was most important. Our study was not powered to detect
differences in hard outcomes following TAVI. Patient
selection is critical and an extremely important aspect of a
successful TAVI program. In our experience, more patients
are turned down for TAVI than are accepted into the
program, as we look to critically select patients who will do
well post-procedure and in the long term. Reasons for
declining enrollment into the trial include the presence of
significant comorbidities, borderline peripheral vessels with
concomitant poor surgical candidacy, and significant mitral
or tricuspid valve disease. At our center, a large number of
patients evaluated for the PARTNER trial were offered and
underwent surgical AVR. We have gained enormous expe-
rience in being able to select patients who are likely to do
well, and improvement in patient selection is part of our
learning curve related to case selection.
Because the TAVI team is large, effective communication
before, during, and after the procedure has been crucial. The
patient is usually seen pre-procedure by a cardiologist,
interventional cardiologist, cardiac surgeon, anesthesiolo-
gist, and the coordinating nurse with the purpose of
recognizing and treating all baseline comorbidities as ap-
propriate. Similarly, the pre-procedural tests and imaging
procedures have been refined using transesophageal echo-
cardiography (TEE) to determine left ventricular outflow
tract and aortic annular size, using CT imaging for assess-
ment of peripheral vasculature. In our practice, borderline
caliber peripheral vessels that technically meet enrollment
criteria require subjective assessment of whether they are
likely to straighten and accept the large-caliber vascular
sheaths. With experience, we tended to preferentially shunt
such patients to the transapical approach, thus reducing the
risk of potentially catastrophic vascular complications in
these patients. The use of smaller delivery sheaths in the
future may obviate the need for a surgical cutdown and
exposure of the femoral vessels and make access site com-
plications less frequent and easier to manage.
In our experience, as well as that of others, an overall
increase in the comfort level of the entire team involved in
the procedure occurs based on ease and familiarity with the
procedure details and sequences. All patients in the cohort
had the same sequence of procedures performed during
valve implantation; however, we observed less repetition of
aortograms and fewer pacing runs as selection of optimal
projections became easier and quicker with experience.
Similarly, cardiac catheterization technicians are familiar
with the equipment and setup necessary; nurses/cardiac
anesthesiologists are more comfortable and easily trouble-
shoot and manage intraprocedural changes in patients’
hemodynamics; and the interventional cardiologists/cardiacsurgeons are increasingly aware of and are able to recognize
and manage complications.
It should be noted that all our patients obtained pre-
procedural imaging consisting of contrast CT of the heart
and peripheral vasculature, TEE, and coronary angiogra-
phy. The use of pre-procedural CT to pre-plan our angio-
graphic views for valve deployment has also decreased the
use of multiple aortograms to determine the appropriate
angiographic views, subsequently decreasing our contrast
volume and radiation dose. With increasing experience, less
time is spent positioning the valve, which has led to a
decrease in the frequency of pacing runs before valve
deployment. The use of the information obtained from our
pre-procedural imaging techniques aid in planning the
procedure beforehand. The best access site for the valve
delivery system is predetermined. The optimal projection
for visibility of all 3 aortic cusps is also predetermined with
the aid of 3-dimensional CT reconstruction. Planning for
and managing potential complications like left main occlu-
sion or major vascular complications is easier as a detailed
assessment of the cardiac and peripheral vasculature is
performed before performing the procedure.
Intraprocedural imaging using TEE to assess the valve
immediately after valve deployment has also improved;
the noninvasive physician is able to quickly determine
valve position and severity of periprosthetic aortic regur-
gitation on TEE as they have become more comfortable
visualizing these valves. This has decreased the time
interval in which hardware has been left across the new
valve, potentially decreasing thromboembolic complica-
tions/events.
In the last 6 years, there has been tremendous improve-
ment in the valve delivery system and the aortic valve
prosthesis. Smaller, less bulky, and more user-friendly
delivery systems and devices have made the valve implanta-
tion process easier. Translation of the experience and
knowledge gained from highly experienced centers and
operators has been crucial in the training of subsequent
centers. In their recently published series, the Vancouver
group describes the impact of learning curve on procedural
and patient outcomes (36). They report significant improve-
ment in in-hospital and 30-day mortality with increasing
experience but there was no difference in procedural com-
plications between the first and second halves of their series.
The Society of Thoracic Surgeons score in the second half
of their series was also lower than that in the first half,
which likely reflects better patient selection based on expe-
rience. Our series was not powered to detect differences in
hard endpoints such as morbidity and mortality, due to the
small sample size. However, we did clearly observe improve-
ments in the process measures of procedural time, contrast
volume, and radiation exposure. At our center, the rigorous
training and proctorship along with the benefit of early
experience of sites such as Vancouver have made the
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78adoption and transition of this technology to the patient
rather seamless with a significant reduction in the adverse
outcomes seen in the sites that pioneered this technology.
Once the Edwards Sapien valve is approved in the United
States and available for commercial use, issues of training,
proctorship, and credentialing will be vital. The impact of a
significant learning curve cannot be overlooked, as the
efficacy of these devices will depend on both short- and
long-term outcomes of patients treated compared to the
standard surgical aortic valve implantation. Operators in-
volved in implanting these devices will have to be familiar
with the technique of performing aortic valvuloplasty, man-
agement of large bore arterial sheaths and vascular compli-
cations. The number of procedures required to be per-
formed before operators can be certified as being competent
remains to be determined. The current data reveal a plateau
of the proficiency curve with less variation in means (Figs. 1
and 2) suggest that even in experienced centers a learning
urve of at least 20 aortic valvuloplasties and at least 25 to
0 TAVI procedures will be needed for procedural
roficiency. Modes of training will continue to evolve and
ill include the use of simulators, industry-sponsored
raining, proctorship, and dedicated interventional/
tructural heart fellowship training as being proposed by
xperts in the field (37).
Study limitations. This is a retrospective single-center anal-
sis and is subject to the limitations of such analyses. The
ample size is small and may be a limitation in the
nterpretation of the data. This study does not account for
he experience and comfort level of physicians performing
he procedure, which may vary by institution. It also does
ot account for variation in local practices concerning the
eld of percutaneous valve implantation.
onclusions
A learning curve was clearly demonstrable for percutaneous
valve implantation. There were significant decreases in
procedural times, radiation dose, and contrast volume. Our
data show increasing proficiency with evidence of plateau
after the first 30 cases. More studies are needed to confirm
these findings.
Reprint requests and correspondence: Dr. David R. Holmes, Jr.,
Mayo Clinic, 200 First Street SW, Rochester, Minnesota, 55905.
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